AAVantgarde announces its innovative clinical study design for its lead program in Usher 1B AAVantgarde announces its innovative clinical study design for its lead program in Usher 1B

AAVantgarde announces updated NHP data from its Stargardt disease program in a poster presentation at the ARVO 2024 annual meeting AAVantgarde announces updated NHP data from its Stargardt disease program in a poster presentation at the ARVO 2024 annual meeting

AAVantgarde presents positive preclinical data in large animal models from its Stargardt disease program in an oral presentation at the ASGCT 2024 annual meeting AAVantgarde presents positive preclinical data in large animal models from its Stargardt disease program in an oral presentation at ASGCT 2024

AAVantgarde Closes €61 Million Series A Financing to Advance Two Therapeutic Programs into the Clinic - Financing led by Atlas Venture and Forbion - Company created, incubated and seed financed by Sofinnova Partners MILAN, Italy, June 06, 2023 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a...